Baker McKenzie has advised Biocartis Group NV and its group companies on the enforcement by Biocartis's secured creditors. As a result of the process used, the enforcement is  not expected to impact Biocartis's customers, suppliers, partners or employees, allowing it to continue its innovative work in molecular diagnostics.

Baker McKenzie has represented Biocartis from VC-stage through to its 2015 IPO on Brussels Euronext, multiple rounds of convertible bond and debt financing as well as rights offerings, and ultimately a well-managed collateral enforcement against the assets by the secured lenders – a testimony to our high-value cross-practice group, cross-office collaboration.

The Brussels and London based cross-border team, led by Adam Farlow, Michael Van Acker, Roel Meers and Luc Meeus, also included Joren Jansseune, Arne Naert and Max Khrapov, and additional team members in Italy, Hong Kong and North America. 
Explore Our Newsroom